Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model

American Journal of Ophthalmology
Regis P KowalskiY Jerold Gordon

Abstract

The prophylaxis potential of the topical antibiotic, 0.5% moxifloxacin (Vigamox), was evaluated to prevent endophthalmitis after bacterial anterior chamber challenge in a rabbit model. An in vivo laboratory investigation. Three regimens of topical 0.5% moxifloxacin were tested for prophylaxis to prevent endophthalmitis: (1) (full prophylaxis) moxifloxacin drops every 15 minutes for 1 hour (five drops), anterior chamber challenge with 5 x 10(4) colony-forming units of Staphylococcus aureus, one drop of moxifloxacin, and four more drops applied over the next 24 hours; (2) (preprophylaxis) prechallenge prophylaxis, S. aureus challenge, and no postchallenge prophylaxis; and (3) (postprophylaxis) no prechallenge prophylaxis, S. aureus challenge, and postchallenge prophylaxis. A saline control was tested concurrently in all three experiments. At 24 hours after injection, the eyes were evaluated by slit lamp in a masked fashion for clinical signs of endophthalmitis, and the anterior and posterior chambers were cultured for bacteria. The median clinical scores for the moxifloxacin group were significantly lower than the saline group for all three treatment regimens. The median clinical score for the full prophylaxis regimen was signifi...Continue Reading

References

Feb 13, 1999·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·R BeckB Drewelow
Apr 5, 2002·American Journal of Ophthalmology·Rookaya MatherRegis P Kowalski
Nov 16, 2002·Current Eye Research·Masakazu YamadaYukihiko Mashima
Jan 21, 2003·Emerging Infectious Diseases·W Michael Scheld
Mar 29, 2003·Journal of Cataract and Refractive Surgery·Ilgaz Sagdic YalvacSunay Duman

❮ Previous
Next ❯

Citations

Jun 23, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Daniel S Durrie, William Trattler
May 26, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Luis E Fernández de CastroKerry D Solomon
Mar 29, 2008·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Regis P KowalskiY Jerold Gordon
Sep 23, 2008·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Edward F SmithIssa Eid
Jun 23, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Erin W NorcrossMary E Marquart
Nov 15, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Xianggen WuLingjuan Xu
Dec 24, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Soon-Phaik Chee
Aug 29, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Regis P KowalskiFrancis S Mah
Dec 20, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Yoshitaka TasakaYuichi Ohashi
Jul 18, 2006·Eye & Contact Lens·Linda T LyW Matthew Petroll
Mar 11, 2005·Expert Review of Anti-infective Therapy·Regis P Kowalski, Deepinder K Dhaliwal
Feb 20, 2013·Expert Opinion on Drug Delivery·Pravin PawarDipak K Majumdar
Jul 22, 2010·Expert Opinion on Drug Delivery·Fernando PaganelliUNKNOWN Brazilian Ocular Pharmacology and Pharmaceutical Technology Research Group
Jul 16, 2005·Current Eye Research·Y Jerold GordonAlison M McDermott
Jul 26, 2011·Journal of Cataract and Refractive Surgery·Mark PackerUNKNOWN ASCRS Cataract Clinical Committee
Jun 6, 2009·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·John C Lloyd, Rosa Braga-Mele
May 13, 2008·Journal of Cataract and Refractive Surgery·Brian HaugenRandall J Olson
Feb 27, 2008·Journal of Cataract and Refractive Surgery·Thomas J Liesegang
Sep 25, 2007·Journal of Cataract and Refractive Surgery·Terrence P O'BrienFrancis S Mah
Oct 19, 2004·American Journal of Ophthalmology·Rookaya MatherStephen D McLeod
Aug 9, 2005·American Journal of Ophthalmology·Regis P KowalskiY Jerold Gordon
Nov 1, 2005·Survey of Ophthalmology·Eduardo Alfonso, Julie Crider
Sep 23, 2006·American Journal of Ophthalmology·Vincent A DeramoIra J Udell
May 8, 2016·Progress in Retinal and Eye Research·Roger A AstleyMichelle C Callegan
Sep 26, 2017·Eye & Contact Lens·Siwei ZhouRobert M Q Shanks
Feb 19, 2005·The Tohoku Journal of Experimental Medicine·Sitki Samet ErmisFaruk Ozturk
Oct 25, 2006·International Ophthalmology Clinics·Terrence P O'Brien
Apr 24, 2007·International Ophthalmology Clinics·Jae Yong KimBonnie An Henderson
May 17, 2011·Expert Review of Ophthalmology·Billy D Novosad, Michelle C Callegan
Jan 15, 2005·Current Opinion in Ophthalmology·Eduardo S Soriano, Mauro Nishi
Dec 23, 2016·Journal of Cataract and Refractive Surgery·Steve A Arshinoff, Milad Modabber
Jan 11, 2020·Survey of Ophthalmology·Shriji N PatelStephen J Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.